Back to results
US 2025/0129342 A1Published application
Alphavirus replicon particle
AssigneeVLP Therapeutics, LLC
InventorsWataru AKAHATA, Ryuji UENO
Life of this patent
Estimating the term…
Abstract
Provided is an alphavirus replicon particle (ARP), which comprises (i) alphavirus structural proteins comprising capsid and/or envelope, and (ii) an alphavirus replicon comprising a polynucleotide encoding alphavirus non-structural proteins nspl, nsp2, nsp3 and nsp4 and at least one gene of interest wherein at least one of capsid, and E3 and E2 in the envelope comprise one or more amino acid alteration but El in the envelope comprises no amino acid alteration.
Claims19
An alphavirus replicon particle (ARP), which comprises
- (i) alphavirus structural proteins, wherein said alphavirus structural proteins comprise capsid protein, and E1 and E2 envelope proteins, and
- (ii) an alphavirus replicon comprising a polynucleotide encoding alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and at least one gene of interest,
- wherein said alphavirus capsid protein contains a mutation in the Nuclear Localization Signal (NLS), and wherein said mutation is the substitution of lysine with asparagine at the position corresponding to position 64 of VEEV virus capsid protein.
An alphavirus replicon particle (ARP), which comprises
- (i) CHIKV structural proteins, wherein said CHIKV structural proteins comprise capsid protein, and E1 and E2 envelope proteins, and
- (ii) a VEEV replicon comprising a polynucleotide encoding VEEV non-structural proteins nsp1, nsp2, nsp3 and nsp4 and at least one gene of interest.
Dependencies are inferred from the claim text.